KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short-term Investments: 2020-2025

Historic Short-term Investments for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $16.1 million.

  • Royalty Pharma's Short-term Investments fell 66.80% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year decrease of 66.80%. This contributed to the annual value of $58.2 million for FY2024, which is 218.03% up from last year.
  • Per Royalty Pharma's latest filing, its Short-term Investments stood at $16.1 million for Q3 2025, which was up 21.97% from $13.2 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Short-term Investments high stood at $409.3 million for Q3 2022, and its period low was $1.3 million during Q4 2022.
  • In the last 3 years, Royalty Pharma's Short-term Investments had a median value of $16.1 million in 2025 and averaged $22.4 million.
  • The largest annual percentage gain for Royalty Pharma's Short-term Investments in the last 5 years was 1,307.69% (2023), contrasted with its biggest fall of 98.71% (2023).
  • Over the past 5 years, Royalty Pharma's Short-term Investments (Quarterly) stood at $66.0 million in 2021, then tumbled by 98.03% to $1.3 million in 2022, then spiked by 1,307.69% to $18.3 million in 2023, then spiked by 218.03% to $58.2 million in 2024, then crashed by 66.80% to $16.1 million in 2025.
  • Its Short-term Investments was $16.1 million in Q3 2025, compared to $13.2 million in Q2 2025 and $12.1 million in Q1 2025.